Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …

Importance The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide
and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment …

Background Despite advancements in care, many people with type 2 diabetes do not meet
treatment goals; thus, development of new therapies is needed. We aimed to assess …

Metabolic homeostasis in mammals is tightly regulated by the complementary actions of
insulin and glucagon. The secretion of these hormones from pancreatic β-cells and α-cells …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver
disease. There has been important progress in the field in recent years and the complexity of …

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …